世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

抗菌薬耐性サーベイランス市場：ソリューション別（キット、システム、サーベイランスソフトウェア、サービス）、用途別（臨床診断、公衆衛生サーベイランス）、エンドユーザー別（病院、診療所、学術、研究機関） - 2028年までの世界予測


Antimicrobial Resistance Surveillance Market by Solution (Kits, System, Surveillance Software, Service), Application (Clinical Diagnostics, Public Health Surveillance), End User (Hospitals, Clinics, Academic, Research Institutes) - Global Forecast to 2028

世界の抗菌薬耐性サーベイランス市場は、2023年の59億米ドルから2028年には77億米ドルに達すると予測され、予測期間中の年平均成長率は5.6%である。この市場の成長は、薬剤耐性病原体による感染症の蔓延、診断技... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2023年9月19日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		200 163 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界の抗菌薬耐性サーベイランス市場は、2023年の59億米ドルから2028年には77億米ドルに達すると予測され、予測期間中の年平均成長率は5.6%である。この市場の成長は、薬剤耐性病原体による感染症の蔓延、診断技術の革新、抗菌薬耐性の脅威の高まり、抗菌薬耐性菌と闘うための政府のイニシアチブの高まり、薬物乱用による多剤耐性の出現などの要因によってもたらされます。一方、抗菌薬耐性診断システムやキットに関連する高コストなどの要因が、この市場の成長を制限している。

2023年には、診断キット分野が抗菌薬耐性サーベイランス市場で最大のシェアを占めると予測されている。

ソリューション別では、世界の抗菌薬耐性サーベイランス市場は診断キット、診断システム、サーベイランスソフトウェア、サービスに区分される。2023年には、診断キット分野が世界の抗菌薬耐性サーベイランス市場で最大のシェアを占めると推定される。このセグメントの大きなシェアは主に、早期発見と治療のニーズの高まり、抗菌薬耐性の迅速診断の需要の増加、抗菌薬耐性動向のサーベイランスと追跡に不可欠なデータの必要性に起因している。

臨床診断は2023年に抗菌薬耐性監視市場で最大のシェアを占めると予測される

用途別では、世界の抗菌薬耐性サーベイランス市場は、臨床診断、公衆衛生サーベイランス、その他の用途に区分される。2023年には、臨床診断分野が世界の抗菌薬耐性サーベイランス市場で最大のシェアを占めると予測されている。このセグメントの成長は、より良い患者転帰への嗜好の高まり、抗菌薬耐性の蔓延などの要因に起因する。

エンドユーザー別では、病院と診療所が最大シェアを占める
エンドユーザー別では、世界の抗菌薬耐性サーベイランス市場は病院・診療所、研究・学術機関、その他に区分される。2023年には、病院・診療所セグメントが世界の抗菌薬耐性サーベイランス市場で最大のシェアを占めた。このセグメントの大きなシェアは、病院・診療所における患者密度の高さ、病院内での院内感染の増加、感染制御プロトコルの維持に起因している。

地域別では北米が最大シェアを占めると予測される
地域別では、世界の抗菌薬耐性サーベイランスは、北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカに区分される。2023年には、北米の抗菌薬耐性サーベイランス市場が世界の抗菌薬耐性サーベイランス市場で最大のシェアを占めると予測されている。これは、大手市場プレイヤーの存在、抗菌薬耐性の最も高い普及率、および強力な規制環境に起因する。

主要参入企業の内訳は以下の通りである：
- 企業タイプ別 - ティア1-40％、ティア2-30％、ティア3-30
- 役職別 - Cレベル-27%、ディレクターレベル-18%、その他-55
- 地域別 - 北米-45%、欧州-15%、アジア太平洋地域-25%、中東・アフリカ-5%、ROW-10

抗菌薬耐性サーベイランス市場の主要企業
抗菌薬耐性サーベイランス市場の主要プレーヤーは、Qiagen（ドイツ）、Luminex Corporation（米国）、Roche Diagnostics（スイス）、OpGen, Inc.(米国）、Abbott Laboratories（米国）、Bruker（米国）、Merck KgaA（ドイツ）、Bio-Rad（米国）、Danaher（米国）、Bioanalyse（トルコ）、Biomerieux（フランス）、Thermo Fisher Scientific（米国）、Becton, Dickinson and Company（米国）、BioSpace（米国）、Cepheid（米国）、Accelerate Diagnostics, Inc.（米国）、Liofilchem S.r.l.（イタリア）、Alifax S.r.l.（イタリア）。

調査範囲
当レポートでは、抗菌薬耐性サーベイランス市場を分析し、ソリューション、アプリケーション、エンドユーザーなど様々なセグメントに基づいて、市場規模や今後の成長可能性を推計することを目的としています。また、市場で入手可能な様々な抗菌薬耐性監視製品の製品ポートフォリオマトリックスも掲載しています。また、本レポートでは、本市場における主要企業の競合分析も行っており、企業プロフィール、サービス内容、主要な市場戦略などを掲載しています。
レポート購入の理由
本レポートは、既存企業だけでなく、新規参入企業や小規模企業にとっても、市場の動向を把握する上で有益であり、ひいては市場シェアを拡大する上で役立ちます。本レポートを購入される企業は、以下の戦略のいずれか、または任意の組み合わせを使用して、市場での地位を強化することができます。

本レポートは、以下のポイントに関する洞察を提供する：
抗菌薬耐性サーベイランス市場の成長に影響を与える主な促進要因（薬剤耐性病原体による感染症の蔓延、診断技術の革新）、阻害要因（抗菌薬耐性診断システム/キットの高コスト）、機会（新興国における成長機会、抗菌薬耐性とその制御に対する意識向上への取り組み）、課題（複雑な規制枠組み）の分析。
- 市場への浸透：世界の抗菌薬耐性監視市場におけるトップ企業が提供する製品ポートフォリオに関する包括的な情報。本レポートでは、この市場をソリューション別、用途別、エンドユーザー別に分析しています。
- サービスの強化/革新：世界の抗菌薬耐性菌監視市場における今後の動向に関する詳細な洞察
- 市場開発：ソリューション別、用途別、エンドユーザー別の有利な新興市場に関する包括的情報。
- 市場の多様化：抗菌薬耐性監視の世界市場における新サービスやサービス強化、成長地域、最新動向、投資に関する詳細情報。
- 競合評価：世界の抗菌薬耐性監視市場における主要企業の市場シェア、成長戦略、製品・サービス内容、企業評価象限、能力などを詳細に評価。

ページTOPに戻る


目次

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS & EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 YEARS CONSIDERED 28
1.4 CURRENCY 29
TABLE 1 STANDARD CURRENCY CONVERSION RATES 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 29
1.7 RECESSION IMPACT ON ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH APPROACH 31
FIGURE 1 RESEARCH DESIGN 31
2.1.1 SECONDARY RESEARCH 31
2.1.1.1 Key data from secondary sources 32
2.1.2 PRIMARY DATA 33
FIGURE 2 PRIMARY SOURCES 33
2.1.2.1 Key data from primary sources 34
2.1.2.2 Insights from primary experts 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.2 MARKET SIZE ESTIMATION 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 36
FIGURE 5 BOTTOM-UP APPROACH 37
FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2023–2028) 38
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 38
2.3 APPROACH USED TO DETERMINE IMPACT OF ECONOMIC RECESSION 39
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 40
FIGURE 8 MARKET DATA TRIANGULATION METHODOLOGY 40
2.5 MARKET SHARE ANALYSIS 41
2.6 STUDY ASSUMPTIONS 41
2.7 RESEARCH LIMITATIONS 41
2.7.1 METHODOLOGY-RELATED LIMITATIONS 41
2.8 RISK ASSESSMENT 41
TABLE 2 RISK ASSESSMENT: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET 41
3 EXECUTIVE SUMMARY 42
FIGURE 9 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2023 VS. 2028 (USD MILLION) 42
FIGURE 10 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 43
FIGURE 11 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 43
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET 44
4 PREMIUM INSIGHTS 45
4.1 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OVERVIEW 45
FIGURE 13 GROWING PREVALENCE OF INFECTIONS CAUSED BY DRUG-RESISTANT PATHOGENS TO DRIVE MARKET GROWTH 45
4.2 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION 46
FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023–2028) 46
4.3 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION AND COUNTRY (2022) 47
FIGURE 15 CLINICAL DIAGNOSTICS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET IN 2022 47
4.4 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: GEOGRAPHIC MIX 48
FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 48
4.5 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DEVELOPED VS. EMERGING ECONOMIES 49
FIGURE 17 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
FIGURE 18 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.1.1 DRIVERS 50
5.1.1.1 Growing prevalence of infections caused by drug-resistant pathogens 50
5.1.1.2 Innovations in diagnostic technologies 51
5.1.1.3 Growing government initiatives to combat antimicrobial-resistant species 52
5.1.1.4 Emergence of multi-drug resistance due to drug abuse 52
5.1.2 RESTRAINTS 53
5.1.2.1 High cost of antimicrobial resistance diagnostic systems/kits 53
5.1.3 OPPORTUNITIES 53
5.1.3.1 Growth opportunities in emerging economies 53
5.1.3.2 Awareness initiatives for antimicrobial resistance and control 54
5.1.4 CHALLENGES 54
5.1.4.1 Complex regulatory frameworks 54
5.2 TECHNOLOGY ANALYSIS 55
5.2.1 REAL-TIME SURVEILLANCE PLATFORMS 55
5.2.2 CRISPR-CAS SYSTEMS 56
5.2.3 AI-POWERED MOBILE APPLICATIONS 56
5.3 PRICING ANALYSIS 57
5.3.1 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS 57
FIGURE 19 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS 57
TABLE 3 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS 57
5.3.2 AVERAGE SELLING PRICE TREND, BY REGION 58
TABLE 4 AVERAGE SELLING PRICE OF ANTIMICROBIAL RESISTANCE SURVEILLANCE SOLUTIONS, BY REGION 58
5.4 VALUE CHAIN ANALYSIS 58
FIGURE 20 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: VALUE CHAIN ANALYSIS 58
5.5 SUPPLY CHAIN ANALYSIS 59
FIGURE 21 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: SUPPLY CHAIN ANALYSIS 59
5.6 ECOSYSTEM ANALYSIS 60
FIGURE 22 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: ECOSYSTEM MARKET MAP 60
5.7 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 5 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.7.1 THREAT OF NEW ENTRANTS 60
5.7.2 THREAT OF SUBSTITUTES 61
5.7.3 BARGAINING POWER OF BUYERS 61
5.7.4 BARGAINING POWER OF SUPPLIERS 61
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.8 TARIFF AND REGULATORY ANALYSIS 61
5.8.1 TARIFF FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE DIAGNOSTIC SYSTEMS 61
TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
5.8.2 REGULATORY ANALYSIS 62
5.8.2.1 North America 62
5.8.2.1.1 US 62
TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION 63
TABLE 8 US: TIME, COST, AND COMPLEXITY OF REGISTRATION 63
5.8.2.1.2 Canada 64
TABLE 9 CANADA: MEDICAL DEVICE CLASSIFICATION 64
TABLE 10 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION 64
5.8.2.2 Europe 64
5.8.2.3 Asia Pacific 65
5.8.2.3.1 Japan 65
5.8.2.3.2 China 65
TABLE 11 CHINA: MEDICAL DEVICE CLASSIFICATION 65
5.8.2.3.3 India 67
5.9 PATENT ANALYSIS 67
5.9.1 PATENT PUBLICATION TRENDS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PRODUCTS 67
FIGURE 23 PATENT PUBLICATION TRENDS (JANUARY 2011–AUGUST 2023) 68
5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 68
FIGURE 24 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PATENTS (JANUARY 2011–AUGUST 2023) 69
FIGURE 25 TOP APPLICANTS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PATENTS (COUNTRY/REGION) (JANUARY 2011–AUGUST 2023) 70
TABLE 12 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: LIST OF PATENTS (2020–2023) 70
5.10 KEY CONFERENCES & EVENTS IN 2023–2024 71
TABLE 13 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DETAILED LIST OF CONFERENCES & EVENTS IN 2023–2024 71
5.11 TRADE ANALYSIS 72
5.11.1 TRADE ANALYSIS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE DIAGNOSTIC SYSTEMS 72
FIGURE 26 IMPORTS OF PRODUCTS UNDER HSN CODE: 90278090, BY COUNTRY, 2022 (USD THOUSAND) 72
FIGURE 27 EXPORTS OF PRODUCTS UNDER HSN CODE: 90278090, BY COUNTRY, 2022 (USD THOUSAND) 72
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 73
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 73
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS 73
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS (%) 73
5.12.2 BUYING CRITERIA 74
FIGURE 29 KEY BUYING CRITERIA FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS 74
TABLE 15 KEY BUYING CRITERIA FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS 74
6 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION 75
6.1 INTRODUCTION 76
TABLE 16 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 76
6.2 DIAGNOSTIC KITS 76
6.2.1 RISING AWARENESS OF AMR TO DRIVE MARKET GROWTH 76
TABLE 17 DIAGNOSTIC KITS OFFERED BY KEY PLAYERS 77
TABLE 18 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR DIAGNOSTIC KITS, BY COUNTRY, 2021–2028 (USD MILLION) 77
6.3 DIAGNOSTIC SYSTEMS 78
6.3.1 GROWING THREAT OF ANTIBIOTIC RESISTANCE TO ACCELERATE MARKET GROWTH 78
TABLE 19 DIAGNOSTIC SYSTEMS OFFERED BY KEY PLAYERS 78
TABLE 20 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR DIAGNOSTIC SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 79
6.4 SURVEILLANCE & ANALYTICS SOFTWARE 79
6.4.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH 79
TABLE 21 SURVEILLANCE & ANALYTICS SOFTWARE OFFERED BY KEY PLAYERS 80
TABLE 22 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR SURVEILLANCE & ANALYTICS SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 80
6.5 OTHER SOLUTIONS 81
TABLE 23 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER SOLUTIONS, BY COUNTRY, 2021–2028 (USD MILLION) 81
7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION 82
7.1 INTRODUCTION 83
TABLE 24 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 83
7.2 CLINICAL DIAGNOSTICS 83
7.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH 83
TABLE 25 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 84
7.3 PUBLIC HEALTH SURVEILLANCE 85
7.3.1 GOVERNMENT INITIATIVES TO ACCELERATE MARKET GROWTH 85
TABLE 26 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR PUBLIC HEALTH SURVEILLANCE, BY COUNTRY, 2021–2028 (USD MILLION) 85
7.4 OTHER APPLICATIONS 86
TABLE 27 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 86
8 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER 87
8.1 INTRODUCTION 88
TABLE 28 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 88
8.2 HOSPITALS & CLINICS 88
8.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 88
TABLE 29 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 89
8.3 RESEARCH & ACADEMIC INSTITUTES 90
8.3.1 GROWING RESEARCH GRANTS AND FUNDING TO ACCELERATE MARKET GROWTH 90
TABLE 30 FUNDING BY DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020 90
TABLE 31 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 91
8.4 OTHER END USERS 91
TABLE 32 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 92
9 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION 93
9.1 INTRODUCTION 94
TABLE 33 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION, 2021–2028 (USD MILLION) 94
9.2 NORTH AMERICA 94
FIGURE 30 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SNAPSHOT 95
TABLE 34 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 35 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 96
TABLE 36 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 96
TABLE 37 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 97
9.2.1 US 97
9.2.1.1 US to dominate North American market during forecast period 97
TABLE 38 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 98
TABLE 39 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 98
TABLE 40 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 99
9.2.2 CANADA 99
9.2.2.1 Favorable government initiatives to drive growth during forecast period 99
TABLE 41 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 100
TABLE 42 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100
TABLE 43 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 101
9.2.3 NORTH AMERICA: RECESSION IMPACT 101
9.3 EUROPE 101
TABLE 44 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 45 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 102
TABLE 46 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 103
TABLE 47 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.3.1 GERMANY 103
9.3.1.1 Germany to dominate European market during forecast period 103
TABLE 48 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 104
TABLE 49 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 104
TABLE 50 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 105
9.3.2 UK 105
9.3.2.1 Significant prevalence of infectious diseases coupled with increasing awareness to drive market growth 105
TABLE 51 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 106
TABLE 52 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 106
TABLE 53 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.3.3 FRANCE 107
9.3.3.1 Supportive government policies and easy accessibility to healthcare services to fuel growth 107
TABLE 54 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 108
TABLE 55 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 108
TABLE 56 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.3.4 ITALY 109
9.3.4.1 Increasing R&D investments by pharmaceutical companies to propel demand 109
TABLE 57 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 110
TABLE 58 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
TABLE 59 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 111
9.3.5 SPAIN 111
9.3.5.1 Rising geriatric population to drive market growth 111
TABLE 60 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 112
TABLE 61 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 62 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 113
9.3.6 REST OF EUROPE 113
TABLE 63 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 113
TABLE 64 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 114
TABLE 65 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 114
9.3.7 EUROPE: RECESSION IMPACT 114
9.4 ASIA PACIFIC 115
FIGURE 31 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SNAPSHOT 116
TABLE 66 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 67 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 117
TABLE 68 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 118
TABLE 69 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 118
9.4.1 JAPAN 118
9.4.1.1 Growing geriatric population to drive market 118
TABLE 70 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 119
TABLE 71 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 119
TABLE 72 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 120
9.4.2 CHINA 120
9.4.2.1 Favorable government regulations and heavy burden of infectious diseases to drive market growth 120
TABLE 73 INCIDENCE OF INFECTIOUS DISEASES IN CHINA, 2020 120
TABLE 74 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 121
TABLE 75 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 76 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 122
9.4.3 INDIA 122
9.4.3.1 Growing initiatives for clinical diagnosis by government and major players to drive market growth 122
TABLE 77 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 123
TABLE 78 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 123
TABLE 79 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 124
9.4.4 REST OF ASIA PACIFIC 124
TABLE 80 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 124
TABLE 81 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 125
TABLE 82 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 125
9.4.5 ASIA PACIFIC: RECESSION IMPACT 125
9.5 LATIN AMERICA 126
9.5.1 GROWING ECONOMIC DEVELOPMENT TO DRIVE MARKET GROWTH 126
9.5.2 LATIN AMERICA: RECESSION IMPACT 126
TABLE 83 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 126
TABLE 84 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 127
TABLE 85 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 127
9.6 MIDDLE EAST & AFRICA 127
9.6.1 GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH 127
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 128
TABLE 86 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 128
TABLE 87 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 128
TABLE 88 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 129
10 COMPETITIVE LANDSCAPE 130
10.1 INTRODUCTION 130
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 130
TABLE 89 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET 131
10.3 REVENUE SHARE ANALYSIS 132
FIGURE 32 REVENUE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2018–2022) 132
10.4 MARKET SHARE ANALYSIS 132
FIGURE 33 MARKET SHARE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2022) 133
10.5 COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS (2022) 134
10.5.1 STARS 134
10.5.2 EMERGING LEADERS 135
10.5.3 PERVASIVE PLAYERS 135
10.5.4 PARTICIPANTS 135
FIGURE 34 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 135
10.5.5 COMPANY FOOTPRINT 136
TABLE 90 COMPANY FOOTPRINT ANALYSIS, BY SOLUTION 136
TABLE 91 COMPANY FOOTPRINT ANALYSIS, BY APPLICATION 137
TABLE 92 COMPANY FOOTPRINT ANALYSIS, BY END USER 138
TABLE 93 COMPANY FOOTPRINT ANALYSIS, BY REGION 139
10.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 140
10.6.1 PROGRESSIVE COMPANIES 140
10.6.2 RESPONSIVE COMPANIES 140
10.6.3 DYNAMIC COMPANIES 140
10.6.4 STARTING BLOCKS 140
FIGURE 35 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS, 2022 141
10.6.5 COMPETITIVE BENCHMARKING 141
TABLE 94 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY FOOTPRINT OF KEY PLAYERS 141
10.7 COMPETITIVE SCENARIO 142
10.7.1 PRODUCT LAUNCHES 142
TABLE 95 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–SEPTEMBER 2023 143
10.7.2 DEALS 144
TABLE 96 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DEALS, JANUARY 2020–SEPTEMBER 2023 144
11 COMPANY PROFILES 145
11.1 KEY PLAYERS 145
(Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses & Competitive threats)*
11.1.1 BIOMÉRIEUX SA 145
TABLE 97 BIOMÉRIEUX SA: BUSINESS OVERVIEW 145
FIGURE 36 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2022) 146
11.1.2 THERMO FISHER SCIENTIFIC INC. 150
TABLE 98 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 150
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 151
11.1.3 BECTON, DICKINSON AND COMPANY 154
TABLE 99 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 154
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 155
11.1.4 DANAHER CORPORATION 158
TABLE 100 DANAHER CORPORATION: BUSINESS OVERVIEW 158
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 159
11.1.5 BIO-RAD LABORATORIES, INC. 162
TABLE 101 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 162
FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 163
11.1.6 LUMINEX CORPORATION 165
TABLE 102 LUMINEX CORPORATION: BUSINESS OVERVIEW 165
FIGURE 41 LUMINEX CORPORATION: COMPANY SNAPSHOT (2022) 165
11.1.7 BRUKER CORPORATION 167
TABLE 103 BRUKER CORPORATION: BUSINESS OVERVIEW 167
FIGURE 42 BRUKER CORPORATION: COMPANY SNAPSHOT (2022) 168
11.1.8 ROCHE DIAGNOSTICS (A DIVISION OF F-HOFFMAN-LA ROCHE LTD.) 170
TABLE 104 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 170
FIGURE 43 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2022) 171
11.1.9 T2 BIOSYSTEMS, INC. 173
TABLE 105 T2 BIOSYSTEMS, INC.: BUSINESS OVERVIEW 173
FIGURE 44 T2 BIOSYSTEMS, INC.: COMPANY SNAPSHOT (2022) 173
11.1.10 MERCK KGAA 175
TABLE 106 MERCK KGAA: BUSINESS OVERVIEW 175
FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022) 176
11.1.11 ACCELERATE DIAGNOSTICS, INC. 178
TABLE 107 ACCELERATE DIAGNOSTICS, INC.: BUSINESS OVERVIEW 178
FIGURE 46 ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022) 178
11.1.12 BIOANALYSE 180
TABLE 108 BIOANALYSE: BUSINESS OVERVIEW 180
11.1.13 HIMEDIA LABORATORIES 181
TABLE 109 HIMEDIA LABORATORIES: BUSINESS OVERVIEW 181
11.1.14 LIOFILCHEM S.R.L. 183
TABLE 110 LIOFILCHEM S.R.L.: BUSINESS OVERVIEW 183
11.1.15 ALIFAX S.R.L. 186
TABLE 111 ALIFAX S.R.L.: BUSINESS OVERVIEW 186
11.1.16 WOLTERS KLUWER N.V. 188
TABLE 112 WOLTERS KLUWER N.V.: BUSINESS OVERVIEW 188
FIGURE 47 WOLTERS KLUWER N.V.: COMPANY SNAPSHOT (2022) 189
11.1.17 OPGEN, INC. 190
TABLE 113 OPGEN, INC.: BUSINESS OVERVIEW 190
FIGURE 48 OPGEN, INC.: COMPANY SNAPSHOT (2022) 190
11.1.18 CREATIVE DIAGNOSTICS 192
TABLE 114 CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW 192
11.1.19 SYNBIOSIS 194
TABLE 115 SYNBIOSIS: BUSINESS OVERVIEW 194
11.2 OTHER PLAYERS 195
11.2.1 ZHUHAI DL BIOTECH CO., LTD. 195
11.2.2 ELITECHGROUP 195
11.2.3 MAST GROUP LTD. 196
11.2.4 CONDALAB 196
11.2.5 GENEFLUIDICS, INC. 197
11.2.6 MP BIOMEDICALS 197
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses & Competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 198
12.1 DISCUSSION GUIDE 198
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 201
12.3 CUSTOMIZATION OPTIONS 203
12.4 RELATED REPORTS 203
12.5 AUTHOR DETAILS 204

　

ページTOPに戻る


　

Summary

The global antimicrobial resistance surveillance market is projected to reach USD 7.7 billion by 2028 from USD 5.9 billion in 2023, at a CAGR of 5.6% during the forecast period. The growth in this market is driven by factors such as the growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies, escalating threat of antimicrobial resistance, growing government initiatives to combat antimicrobial-resistance species, and emergence of multi-drug resistance due to drug abuse. On the other hand, factors such as high cost associated to antimicrobial resistance diagnostic systems and kits are limiting the growth of this market.

In 2023, the diagnostic kits segment is projected to account for the largest share of the antimicrobial resistance surveillance market

By solutions, the global antimicrobial resistance surveillance market has been segmented into diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the diagnostic kits segment is estimated to command the largest share of the global antimicrobial resistance surveillance market. The large share of this segment can primarily be attributed to the rising need for early detection and treatment, increasing demand for rapid diagnostics for antimicrobial resistance, and need of essential data for surveillance and tracking of antimicrobial resistance trends.

Clinical Diagnostics is projected to account for the largest share of the antimicrobial resistance surveillance market in 2023

By application, the global antimicrobial resistance surveillance market has been segmented into clinical diagnostics, public health surveillance, and other applications . In 2023, the clinical diagnostics segment is projected to account for the largest share of the global antimicrobial resistance surveillance market. The growth in this segment can be attributed to factors such as increasing preference for better patient outcomes, and prevalence of antimicrobial resistance.

By end user, hospitals and clinics accounted for the largest share of the market
By end users, the global antimicrobial resistance surveillance market has been segmented into hospitals & clinics, research and academic institutes, and others. In 2023, the hospitals & clinics segment accounted for the largest share of the global antimicrobial resistance surveillance market.The large share of this segment can be attributed to the high patient density in hospitals and clinics, increasing nonsocomial infections in hospitals, and to maintain the infection control protocols.

By region, North America is projected to account for the largest share of the market
By region the global antimicrobial resistance surveillance segmented into—North America, Europe, Asia Pacific, Latin America, and Middle East Africa. In 2023, North American antimicrobial resistance surveillance market is expected to account for the largest share of the global antimicrobial resistance surveillance market. This can be attributed to the presence of leading market players, highest prevalence of antimicrobial resistance, and strong regulatory environment.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–40%, Tier 2–30%, and Tier 3–30%
• By Designation – C-level–27%, Director-level–18%, Others–55%
• By Region – North America–45%, Europe–15%, Asia Pacific–25%, and Middle East & Africa- 5%,ROW- 10%

Key players in the antimicrobial resistance surveillance Market
The prominent players in this market are Qiagen (Germany), Luminex Corporation (US), Roche Diagnostics (Switzerland), OpGen, Inc. (US), Lumed (US), Wolters Kluwer N.V. (US), Abbott Laboratories (US), Bruker (US), Merck KgaA (Germany), Bio-Rad (US), Danaher (US), Bioanalyse (Turkey), Biomerieux (France), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), BioSpace (US), Cepheid (US), Accelerate Diagnostics, Inc. (US), Liofilchem S.r.l. (Italy), and Alifax S.r.l. (Italy).

Research Coverage:
The report analyzes the antimicrobial resistance surveillance Market and aims at estimating the market size and future growth potential of this market based on various segments such as solution, application and end user. The report also includes a product portfolio matrix of various antimicrobial resistance surveillance products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
Analysis of key drivers (growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies), restraints (high cost of antimicrobial resistance diagnostic systems/ kits), opportunities (growth opportunities in emerging countries and awareness initiatives for antimicrobial resistance and its control) and challenges (complex regulatory framework) influencing the growth of antimicrobial resistance surveillance market.
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global antimicrobial resistance surveillance Market. The report analyzes this market by solution, applications, and end user.
• Service Enhancement/Innovation: Detailed insights on upcoming trends in the global antimicrobial resistance surveillance Market
• Market Development: Comprehensive information on the lucrative emerging markets by solutions, applications, and end user.
• Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global antimicrobial resistance surveillance Market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product and service offerings, company evaluation quadrant, and capabilities of leading players in the global antimicrobial resistance surveillance Market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS & EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 YEARS CONSIDERED 28
1.4 CURRENCY 29
TABLE 1 STANDARD CURRENCY CONVERSION RATES 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 29
1.7 RECESSION IMPACT ON ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH APPROACH 31
FIGURE 1 RESEARCH DESIGN 31
2.1.1 SECONDARY RESEARCH 31
2.1.1.1 Key data from secondary sources 32
2.1.2 PRIMARY DATA 33
FIGURE 2 PRIMARY SOURCES 33
2.1.2.1 Key data from primary sources 34
2.1.2.2 Insights from primary experts 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.2 MARKET SIZE ESTIMATION 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 36
FIGURE 5 BOTTOM-UP APPROACH 37
FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2023–2028) 38
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 38
2.3 APPROACH USED TO DETERMINE IMPACT OF ECONOMIC RECESSION 39
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 40
FIGURE 8 MARKET DATA TRIANGULATION METHODOLOGY 40
2.5 MARKET SHARE ANALYSIS 41
2.6 STUDY ASSUMPTIONS 41
2.7 RESEARCH LIMITATIONS 41
2.7.1 METHODOLOGY-RELATED LIMITATIONS 41
2.8 RISK ASSESSMENT 41
TABLE 2 RISK ASSESSMENT: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET 41
3 EXECUTIVE SUMMARY 42
FIGURE 9 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2023 VS. 2028 (USD MILLION) 42
FIGURE 10 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 43
FIGURE 11 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 43
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET 44
4 PREMIUM INSIGHTS 45
4.1 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OVERVIEW 45
FIGURE 13 GROWING PREVALENCE OF INFECTIONS CAUSED BY DRUG-RESISTANT PATHOGENS TO DRIVE MARKET GROWTH 45
4.2 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION 46
FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023–2028) 46
4.3 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION AND COUNTRY (2022) 47
FIGURE 15 CLINICAL DIAGNOSTICS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET IN 2022 47
4.4 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: GEOGRAPHIC MIX 48
FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 48
4.5 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DEVELOPED VS. EMERGING ECONOMIES 49
FIGURE 17 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
FIGURE 18 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.1.1 DRIVERS 50
5.1.1.1 Growing prevalence of infections caused by drug-resistant pathogens 50
5.1.1.2 Innovations in diagnostic technologies 51
5.1.1.3 Growing government initiatives to combat antimicrobial-resistant species 52
5.1.1.4 Emergence of multi-drug resistance due to drug abuse 52
5.1.2 RESTRAINTS 53
5.1.2.1 High cost of antimicrobial resistance diagnostic systems/kits 53
5.1.3 OPPORTUNITIES 53
5.1.3.1 Growth opportunities in emerging economies 53
5.1.3.2 Awareness initiatives for antimicrobial resistance and control 54
5.1.4 CHALLENGES 54
5.1.4.1 Complex regulatory frameworks 54
5.2 TECHNOLOGY ANALYSIS 55
5.2.1 REAL-TIME SURVEILLANCE PLATFORMS 55
5.2.2 CRISPR-CAS SYSTEMS 56
5.2.3 AI-POWERED MOBILE APPLICATIONS 56
5.3 PRICING ANALYSIS 57
5.3.1 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS 57
FIGURE 19 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS 57
TABLE 3 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS 57
5.3.2 AVERAGE SELLING PRICE TREND, BY REGION 58
TABLE 4 AVERAGE SELLING PRICE OF ANTIMICROBIAL RESISTANCE SURVEILLANCE SOLUTIONS, BY REGION 58
5.4 VALUE CHAIN ANALYSIS 58
FIGURE 20 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: VALUE CHAIN ANALYSIS 58
5.5 SUPPLY CHAIN ANALYSIS 59
FIGURE 21 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: SUPPLY CHAIN ANALYSIS 59
5.6 ECOSYSTEM ANALYSIS 60
FIGURE 22 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: ECOSYSTEM MARKET MAP 60
5.7 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 5 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.7.1 THREAT OF NEW ENTRANTS 60
5.7.2 THREAT OF SUBSTITUTES 61
5.7.3 BARGAINING POWER OF BUYERS 61
5.7.4 BARGAINING POWER OF SUPPLIERS 61
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.8 TARIFF AND REGULATORY ANALYSIS 61
5.8.1 TARIFF FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE DIAGNOSTIC SYSTEMS 61
TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
5.8.2 REGULATORY ANALYSIS 62
5.8.2.1 North America 62
5.8.2.1.1 US 62
TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION 63
TABLE 8 US: TIME, COST, AND COMPLEXITY OF REGISTRATION 63
5.8.2.1.2 Canada 64
TABLE 9 CANADA: MEDICAL DEVICE CLASSIFICATION 64
TABLE 10 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION 64
5.8.2.2 Europe 64
5.8.2.3 Asia Pacific 65
5.8.2.3.1 Japan 65
5.8.2.3.2 China 65
TABLE 11 CHINA: MEDICAL DEVICE CLASSIFICATION 65
5.8.2.3.3 India 67
5.9 PATENT ANALYSIS 67
5.9.1 PATENT PUBLICATION TRENDS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PRODUCTS 67
FIGURE 23 PATENT PUBLICATION TRENDS (JANUARY 2011–AUGUST 2023) 68
5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 68
FIGURE 24 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PATENTS (JANUARY 2011–AUGUST 2023) 69
FIGURE 25 TOP APPLICANTS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PATENTS (COUNTRY/REGION) (JANUARY 2011–AUGUST 2023) 70
TABLE 12 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: LIST OF PATENTS (2020–2023) 70
5.10 KEY CONFERENCES & EVENTS IN 2023–2024 71
TABLE 13 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DETAILED LIST OF CONFERENCES & EVENTS IN 2023–2024 71
5.11 TRADE ANALYSIS 72
5.11.1 TRADE ANALYSIS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE DIAGNOSTIC SYSTEMS 72
FIGURE 26 IMPORTS OF PRODUCTS UNDER HSN CODE: 90278090, BY COUNTRY, 2022 (USD THOUSAND) 72
FIGURE 27 EXPORTS OF PRODUCTS UNDER HSN CODE: 90278090, BY COUNTRY, 2022 (USD THOUSAND) 72
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 73
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 73
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS 73
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS (%) 73
5.12.2 BUYING CRITERIA 74
FIGURE 29 KEY BUYING CRITERIA FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS 74
TABLE 15 KEY BUYING CRITERIA FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS 74
6 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION 75
6.1 INTRODUCTION 76
TABLE 16 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 76
6.2 DIAGNOSTIC KITS 76
6.2.1 RISING AWARENESS OF AMR TO DRIVE MARKET GROWTH 76
TABLE 17 DIAGNOSTIC KITS OFFERED BY KEY PLAYERS 77
TABLE 18 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR DIAGNOSTIC KITS, BY COUNTRY, 2021–2028 (USD MILLION) 77
6.3 DIAGNOSTIC SYSTEMS 78
6.3.1 GROWING THREAT OF ANTIBIOTIC RESISTANCE TO ACCELERATE MARKET GROWTH 78
TABLE 19 DIAGNOSTIC SYSTEMS OFFERED BY KEY PLAYERS 78
TABLE 20 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR DIAGNOSTIC SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 79
6.4 SURVEILLANCE & ANALYTICS SOFTWARE 79
6.4.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH 79
TABLE 21 SURVEILLANCE & ANALYTICS SOFTWARE OFFERED BY KEY PLAYERS 80
TABLE 22 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR SURVEILLANCE & ANALYTICS SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 80
6.5 OTHER SOLUTIONS 81
TABLE 23 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER SOLUTIONS, BY COUNTRY, 2021–2028 (USD MILLION) 81
7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION 82
7.1 INTRODUCTION 83
TABLE 24 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 83
7.2 CLINICAL DIAGNOSTICS 83
7.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH 83
TABLE 25 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 84
7.3 PUBLIC HEALTH SURVEILLANCE 85
7.3.1 GOVERNMENT INITIATIVES TO ACCELERATE MARKET GROWTH 85
TABLE 26 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR PUBLIC HEALTH SURVEILLANCE, BY COUNTRY, 2021–2028 (USD MILLION) 85
7.4 OTHER APPLICATIONS 86
TABLE 27 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 86
8 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER 87
8.1 INTRODUCTION 88
TABLE 28 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 88
8.2 HOSPITALS & CLINICS 88
8.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 88
TABLE 29 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 89
8.3 RESEARCH & ACADEMIC INSTITUTES 90
8.3.1 GROWING RESEARCH GRANTS AND FUNDING TO ACCELERATE MARKET GROWTH 90
TABLE 30 FUNDING BY DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020 90
TABLE 31 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 91
8.4 OTHER END USERS 91
TABLE 32 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 92
9 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION 93
9.1 INTRODUCTION 94
TABLE 33 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION, 2021–2028 (USD MILLION) 94
9.2 NORTH AMERICA 94
FIGURE 30 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SNAPSHOT 95
TABLE 34 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 35 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 96
TABLE 36 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 96
TABLE 37 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 97
9.2.1 US 97
9.2.1.1 US to dominate North American market during forecast period 97
TABLE 38 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 98
TABLE 39 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 98
TABLE 40 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 99
9.2.2 CANADA 99
9.2.2.1 Favorable government initiatives to drive growth during forecast period 99
TABLE 41 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 100
TABLE 42 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100
TABLE 43 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 101
9.2.3 NORTH AMERICA: RECESSION IMPACT 101
9.3 EUROPE 101
TABLE 44 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 45 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 102
TABLE 46 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 103
TABLE 47 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.3.1 GERMANY 103
9.3.1.1 Germany to dominate European market during forecast period 103
TABLE 48 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 104
TABLE 49 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 104
TABLE 50 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 105
9.3.2 UK 105
9.3.2.1 Significant prevalence of infectious diseases coupled with increasing awareness to drive market growth 105
TABLE 51 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 106
TABLE 52 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 106
TABLE 53 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.3.3 FRANCE 107
9.3.3.1 Supportive government policies and easy accessibility to healthcare services to fuel growth 107
TABLE 54 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 108
TABLE 55 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 108
TABLE 56 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.3.4 ITALY 109
9.3.4.1 Increasing R&D investments by pharmaceutical companies to propel demand 109
TABLE 57 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 110
TABLE 58 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
TABLE 59 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 111
9.3.5 SPAIN 111
9.3.5.1 Rising geriatric population to drive market growth 111
TABLE 60 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 112
TABLE 61 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 62 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 113
9.3.6 REST OF EUROPE 113
TABLE 63 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 113
TABLE 64 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 114
TABLE 65 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 114
9.3.7 EUROPE: RECESSION IMPACT 114
9.4 ASIA PACIFIC 115
FIGURE 31 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SNAPSHOT 116
TABLE 66 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 67 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 117
TABLE 68 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 118
TABLE 69 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 118
9.4.1 JAPAN 118
9.4.1.1 Growing geriatric population to drive market 118
TABLE 70 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 119
TABLE 71 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 119
TABLE 72 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 120
9.4.2 CHINA 120
9.4.2.1 Favorable government regulations and heavy burden of infectious diseases to drive market growth 120
TABLE 73 INCIDENCE OF INFECTIOUS DISEASES IN CHINA, 2020 120
TABLE 74 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 121
TABLE 75 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 76 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 122
9.4.3 INDIA 122
9.4.3.1 Growing initiatives for clinical diagnosis by government and major players to drive market growth 122
TABLE 77 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 123
TABLE 78 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 123
TABLE 79 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 124
9.4.4 REST OF ASIA PACIFIC 124
TABLE 80 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 124
TABLE 81 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 125
TABLE 82 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 125
9.4.5 ASIA PACIFIC: RECESSION IMPACT 125
9.5 LATIN AMERICA 126
9.5.1 GROWING ECONOMIC DEVELOPMENT TO DRIVE MARKET GROWTH 126
9.5.2 LATIN AMERICA: RECESSION IMPACT 126
TABLE 83 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 126
TABLE 84 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 127
TABLE 85 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 127
9.6 MIDDLE EAST & AFRICA 127
9.6.1 GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH 127
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 128
TABLE 86 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION) 128
TABLE 87 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 128
TABLE 88 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION) 129
10 COMPETITIVE LANDSCAPE 130
10.1 INTRODUCTION 130
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 130
TABLE 89 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET 131
10.3 REVENUE SHARE ANALYSIS 132
FIGURE 32 REVENUE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2018–2022) 132
10.4 MARKET SHARE ANALYSIS 132
FIGURE 33 MARKET SHARE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2022) 133
10.5 COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS (2022) 134
10.5.1 STARS 134
10.5.2 EMERGING LEADERS 135
10.5.3 PERVASIVE PLAYERS 135
10.5.4 PARTICIPANTS 135
FIGURE 34 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 135
10.5.5 COMPANY FOOTPRINT 136
TABLE 90 COMPANY FOOTPRINT ANALYSIS, BY SOLUTION 136
TABLE 91 COMPANY FOOTPRINT ANALYSIS, BY APPLICATION 137
TABLE 92 COMPANY FOOTPRINT ANALYSIS, BY END USER 138
TABLE 93 COMPANY FOOTPRINT ANALYSIS, BY REGION 139
10.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 140
10.6.1 PROGRESSIVE COMPANIES 140
10.6.2 RESPONSIVE COMPANIES 140
10.6.3 DYNAMIC COMPANIES 140
10.6.4 STARTING BLOCKS 140
FIGURE 35 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS, 2022 141
10.6.5 COMPETITIVE BENCHMARKING 141
TABLE 94 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY FOOTPRINT OF KEY PLAYERS 141
10.7 COMPETITIVE SCENARIO 142
10.7.1 PRODUCT LAUNCHES 142
TABLE 95 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–SEPTEMBER 2023 143
10.7.2 DEALS 144
TABLE 96 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DEALS, JANUARY 2020–SEPTEMBER 2023 144
11 COMPANY PROFILES 145
11.1 KEY PLAYERS 145
(Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses & Competitive threats)*
11.1.1 BIOMÉRIEUX SA 145
TABLE 97 BIOMÉRIEUX SA: BUSINESS OVERVIEW 145
FIGURE 36 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2022) 146
11.1.2 THERMO FISHER SCIENTIFIC INC. 150
TABLE 98 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 150
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 151
11.1.3 BECTON, DICKINSON AND COMPANY 154
TABLE 99 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 154
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 155
11.1.4 DANAHER CORPORATION 158
TABLE 100 DANAHER CORPORATION: BUSINESS OVERVIEW 158
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 159
11.1.5 BIO-RAD LABORATORIES, INC. 162
TABLE 101 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 162
FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 163
11.1.6 LUMINEX CORPORATION 165
TABLE 102 LUMINEX CORPORATION: BUSINESS OVERVIEW 165
FIGURE 41 LUMINEX CORPORATION: COMPANY SNAPSHOT (2022) 165
11.1.7 BRUKER CORPORATION 167
TABLE 103 BRUKER CORPORATION: BUSINESS OVERVIEW 167
FIGURE 42 BRUKER CORPORATION: COMPANY SNAPSHOT (2022) 168
11.1.8 ROCHE DIAGNOSTICS (A DIVISION OF F-HOFFMAN-LA ROCHE LTD.) 170
TABLE 104 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 170
FIGURE 43 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2022) 171
11.1.9 T2 BIOSYSTEMS, INC. 173
TABLE 105 T2 BIOSYSTEMS, INC.: BUSINESS OVERVIEW 173
FIGURE 44 T2 BIOSYSTEMS, INC.: COMPANY SNAPSHOT (2022) 173
11.1.10 MERCK KGAA 175
TABLE 106 MERCK KGAA: BUSINESS OVERVIEW 175
FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022) 176
11.1.11 ACCELERATE DIAGNOSTICS, INC. 178
TABLE 107 ACCELERATE DIAGNOSTICS, INC.: BUSINESS OVERVIEW 178
FIGURE 46 ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022) 178
11.1.12 BIOANALYSE 180
TABLE 108 BIOANALYSE: BUSINESS OVERVIEW 180
11.1.13 HIMEDIA LABORATORIES 181
TABLE 109 HIMEDIA LABORATORIES: BUSINESS OVERVIEW 181
11.1.14 LIOFILCHEM S.R.L. 183
TABLE 110 LIOFILCHEM S.R.L.: BUSINESS OVERVIEW 183
11.1.15 ALIFAX S.R.L. 186
TABLE 111 ALIFAX S.R.L.: BUSINESS OVERVIEW 186
11.1.16 WOLTERS KLUWER N.V. 188
TABLE 112 WOLTERS KLUWER N.V.: BUSINESS OVERVIEW 188
FIGURE 47 WOLTERS KLUWER N.V.: COMPANY SNAPSHOT (2022) 189
11.1.17 OPGEN, INC. 190
TABLE 113 OPGEN, INC.: BUSINESS OVERVIEW 190
FIGURE 48 OPGEN, INC.: COMPANY SNAPSHOT (2022) 190
11.1.18 CREATIVE DIAGNOSTICS 192
TABLE 114 CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW 192
11.1.19 SYNBIOSIS 194
TABLE 115 SYNBIOSIS: BUSINESS OVERVIEW 194
11.2 OTHER PLAYERS 195
11.2.1 ZHUHAI DL BIOTECH CO., LTD. 195
11.2.2 ELITECHGROUP 195
11.2.3 MAST GROUP LTD. 196
11.2.4 CONDALAB 196
11.2.5 GENEFLUIDICS, INC. 197
11.2.6 MP BIOMEDICALS 197
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses & Competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 198
12.1 DISCUSSION GUIDE 198
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 201
12.3 CUSTOMIZATION OPTIONS 203
12.4 RELATED REPORTS 203
12.5 AUTHOR DETAILS 204

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（kits）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22　10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.